Myocardial infarction in an urban population: Worse long term prognosis for patients from less affluent residential areas

Journal of Epidemiology and Community Health

Volumn 56, Issue 10, 2002, Pages 785-790

  Tydén, Patrik ^a   Hansen, O ^a   Engstrom G ^a   Hedblad, B ^a   Janzon, L ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH RISK; HEART INFARCTION; QUALITY OF LIFE; RISK FACTOR; SOCIOECONOMIC CONDITIONS; SURVIVAL; URBAN POPULATION;

ADULT; AGED; ARTICLE; COVARIANCE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROGNOSIS; SOCIOECONOMICS; SURVIVAL TIME; URBAN AREA;

AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; POVERTY AREAS; PROGNOSIS; REGISTRIES; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SWEDEN; URBAN HEALTH;

SWEDEN;

EID: 0036786280     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.56.10.785     Document Type: Article

References (50)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997;18:1213-48.
2. Nerbrand C, Svärdsudd K, Hörte LG, et al. Geographical variation of mortality from cardiovascular diseases. The project "Myocardial Infarction in mid-Sweden". Eur Heart J 1991;12:4-9.
3. Hammar N, Ahlbom A, Theorell T. Geographical differences in myocardial infarction incidence in eight Swedish counties, 1976-1981. Epidemiology 1992;3:348-55.
4. Tydén P, Hansen O, Janzon L. Intra-urban variations in incidence and mortality in myocardial infarction. A study from the myocardial infarction register in the city of Malmö, Sweden. Eur Heart J 1998;19:1795-801.
5. Tydén P, Engström G, Hansen O, et al. Geographical pattern of female deaths from myocardial infarction in an urban population: fatal outcome out-of-hospital related to socio-economic deprivation. J Intern Med 2001;250:201-7.
6. Engström G, Berglund G, Göransson M, et al. Distribution and determinants of ischaemic heart disease in an urban population. A study from the myocardial infarction register in Malmö, Sweden. J Intern Med 2000;247:588-96.
7. Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 database. Circulation 1993;88:416-29.
8. Fibrinolytic Therapy Trialists (FTF) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
9. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomised clinical trials. Circulation 1995;91:476-85.
10. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
11. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil 1997;17:222-31.
12. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Progr Cardiovsc Dis 1985;17:335-71.
13. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
14. Alistair SH, Murray GD, Ball SG on behalf of the Airex Study Investigators: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;349:1493-7.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
17. Hansen O, Johansson BW. Epidemiologic aspects of coronary heart disease in Malmö 1935-1988. Am J Epidemiol 1991;133:721-33.
18. The National Board of Health and Welfare. Värdering av diagnoskvaliteten för akut hjärtinfarkt i tre svenska län 1995. Artikelnr 1997-84-8. Stockholm: 1997
19. Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2468-82.
20. Engström G, Jerntorp I, Pessah-Rasmussen H, et al. Geographic distribution of stroke incidence within an urban population: relations to socieconomic circumstances and prevalence of cardiovascular risk factors. Stroke 2001;32:1098-103.
21. Manjer J, Berglund G, Bondesson L, et al. Intra-urban differences in breast cancer mortality: a study from the city of Malmö in Sweden. J Epidemiol Community Health 2000;54:279-85.
22. The Unit of Planning and Statistics, Områdesfakta för Malmö 1991-1996. Malmö: Malmö City Council, 1991-1996.
23. Woodward M. Small area statistics as markers for personal social status in the Scottish heart health study. J Epidemiol Community Health 1996;50:570-6.
24. Engström G, Göransson M, Hansen O, et al. Trends in long-term survival after myocardial infarction: less favourable patterns for patients from deprived areas. J Intern Med 2000;248:425-34.
25. Berglund G, Eimsråhl S, Janzon, et al. Design and feasibility. J Intern Med 1993;233:45-51.
26. Merlo J, Ranstam J, Råstam L, et al. Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain. Eur J Clin Pharmacol 1994;46:393-8.
27. Peltonen M, Rosén M, Lundberg V, et al. Social patterning of myocardial infarction and stroke in Sweden: incidence and survival. Am J Epidemiol 2000;151:283-92.
28. Kunst AE, Mackenbach JP. The size of mortality differences associated with educational level in nine industrialized countries. Am J Public Health 1994;84:932-7.
29. Anderson KM, Wilson P, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62
30. Dawber TR. The Framingham study: the epidemiology of atherosclerotic disease. Cambridge, MA: Harward University Press, 1980.
31. Wannamethee G, Whincup P, Shaper AG, et al. Factors determining case fatality in myocardial infarction "Who dies in a heart attack?" Br Heart J 1995;74:324-31.
32. Njölstad I, Arnesen E. Preinfarction blood pressure and smoking are determinants for fatal outcome of myocardial infarction. Arch Infern Med 1998;158:1326-32.
33. Euroaspire Study Group. Euroaspire. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;18:1569-82.
34. Maggioni AP, Tavazzi L, Fabbri G, et al. Epidemiology of post-infarction risk stratification strategies in a country with low volume ofrevascularisation procedures. The GISSI Prognosis Registry. Eur Heart J 1998;19:1784-94.
35. Nilsson P, Andersson DKG, Andersson P-E, et al. Cardiovascular risk factors in treated hypertensives - a nationwide, cross-sectional study in Sweden. J Intern Med 1993;233:239-45.
36. Engström G, Tydén P, Berglund G, et al. Incidence of myocardial infarction in women. A cohort study of risk factors and modifiers of effect. J Epidemiol Community Health 2000;54:104-7.
37. Suadicani P, Hein HO, Gyntelberg F. Serum validated tobacco use and social inequalities in risk of ischemic heart disease. Int J Epidemiol 1994;23:293-300.
38. Holme I, Helgeland A, Hjermann I, et al. Four year mortality by some socioeconomic indicators: the Oslo study. J Epidemiol Community Health 1980;34:48-52.
39. Marmot MG, Syme SL, Kagan A, et al. Epidemiologic studies of coronary heart disease and stroke in japanese men living in Japan, Hawaii, and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol 1975;102:514-25.
40. Carinci F, Nicolucci A, Ciampi A, et al. Role of interactions between psychological and clinical factors in determining 6-month mortality among patients with acute myocardial infarction. Eur Heart J 1997;18:835-45.
41. Thomas SA, Friedmann E, Wimbush F, et al. Psychological factors and survival in the cardiac arrhythmia trial (CAST): a reexamination. Am J Crit Care 1997;6:116-26.
42. Kawachi I, Colditz GA, Ascherio A, et al. A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA. J Epidemiol Community Health 1996;50:245-51.
43. Friedmann E, Thomas SA. Pet ownership, social support, and one-year survival after acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol 1995;76:1213-17.
44. Berkman LF, Leo-Summers L, Horwitz RI. Emotional support and survival after myocardial infarction. A prospective, population-based study of the elderly. Ann Intern Med 1992;117:1003-9.
45. Nilsson Å, Hanson BS, Isacsson S-O. Public Health Report- Malmö County 1991 (Folkhälsorapport - Malmö kommun 1991). Maimsö: Department of Community Medicine, Malmö University Hospital, 1991.
46. Lindström M, Bexell A, Hanson BS, et al. Public Health Report - Malmö County 1994 (Folkhälsorapport - Malmö kommun 1994). Maimö: Department of Community Medicine, Malmö University Hospital, 1994.
47. Orencia A, Bailey K, Yawn BP, et al. Effect of gender on long-term outcome of angina pectoris and myocardial infarction/sudden unexpected death. JAMA 1993;269:2392-7.
48. Benderly M, Behar S, Reicher-Reiss H, et al for the SPRINT study Group Long-term prognosis of women after myocardial infarction. Am J Epidemiol 1997;146:153-60.
49. Balgent C Collins R, Appeby P, et al. ISIS-2 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316:1337-43.
50. Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow up of the first megatrial testing rhrombolytic therapy in patients with acute myocardial infarction. Circulation 1998;98:2659-65.